STOCKS TELEGRAPH

Author: Maria Masood

  • Here’s What you Should Know About Inclining Early Trading Stock of Viking Therapeutics, Inc. (VKTX).

    Here’s What you Should Know About Inclining Early Trading Stock of Viking Therapeutics, Inc. (VKTX).

    Viking Therapeutics, Inc. (VKTX) is a leading biotherapeutics company engaged in developing treatments for metabolic and endocrine diseases. VK2809 is a lad candidate of the company in Phase 2 trials for treating biopsy-confirmed non-alcoholic steatohepatitis. VK0214 is in Phase 1 trials for treating X-linked adrenoleukodystrophy. VK2735 is in Phase 1 trials for treating metabolic disorders.

    The price of VKTX stock during the regular trading on January 31, 2022, was last checked to be $3.69 with a surge of 3.07%.

    VKTX: Events and Happenings

    On January 24, 2022, VKTX reported about the clinical hold placed by FDA on its lead candidate VK0214. FDA had demanded supplementary preclinical data before the continuation of Phase 1b trials. The company is likely to provide the data in Q2 2022.

    On January 10, 2022, VKTX reported about the commencement of Phase 1 clinical trials for its lead candidate VK2735. On January 3, 2022, VKTX reported that the company’s Executives presented at H.C. Wainwright BioConnect 2022 Conference held on January 10-13, 2022. On November 9, 2021, VKTX reported that the company’s Executives presented at the Virtual Stifel 2021 Healthcare Conference held on November 15-17, 2021.

    VKTX: Key Financials

    On November 3, 2021, VKTX reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 $13.2 million or $0.17 against $9.3 million or $0.13 for the corresponding period in 2020.

    Assets

    Total current assets in Q3 2021 were $224.2 million.

    On November 1, 2021, VKTX reported about the presentation of preclinical results from internally developed dual agonists study at the Virtual ObesityWeek 2021 held on November 1-5, 2021.

    Conclusion

    VKTX stock down performed 39% from the last six months due to the impact of the pandemic on the economy. The current market increase is the outcome of uncertain factors contributing positively to the company’s stock. As the company has shown no recent activity, the financial experts are attributing this gain in stock to the company’s strategies.

  • Imperial Petroleum Inc. (IMPP) Stock Sinking in Premarket. Here’s why.

    Imperial Petroleum Inc. (IMPP) Stock Sinking in Premarket. Here’s why.

    Imperial Petroleum Inc. (IMPP) owns the ships and is one of the largest providers of crude oil and petroleum products. The Company possesses one Aframax oil tanker and three M.R. product freighters with an aggregate capacity of transporting 255,804 deadweight tons.

    The price of IMPP stock during the regular trading on January 31, 2022, was last checked to be $1.07 with a dip of 50.9%.

    IMPP: Events and Happenings

    On January 31, 2022, IMPP reported about its upsized underwritten public offering pricing of 9,600,000 cohorts consisting of one common share and one Class A warrant. The public offering price is $1.25 per cohort. The resultant net proceeds from the offering are anticipated to be up to $12.0 million. The Company aims to utilize the gross proceeds for general corporate purposes.

    IMPP: Key Financials

    On December 21, 2021, IMPP reported its financial results for the third quarter ended September 30, 2021. Some of the key points are as follows.

    Revenue

    Revenue in the third quarter of 2021 was $4.1 million compared to $5.8 million for the same period of 2020. The company’s revenue showed a decline of 29.3% or $1.7 million over the year.

    Net Loss

    Net loss in Q3 2021 was $0.9 million compared to $0.7 million in the same period of 2020.

    Assets

    Total current assets reported for the company in Q3 2021 were $3.65 million.

    IMPP: CEO Comments

    Speaking at the occasion, CEO of IMPP Harry Vafias stated that 2021 had been tough for the company due to uncertainty associated with pandemics resulting in reduced oil and crude exports. He took responsibility for the company’s poor performance in the quarter with a net loss of $1 million. He was also optimistic that the company had the patience to wait until good days.

    On December 16, 2021, IMPP reported a dividend, paid by December 30, 2021, of $0.13 per share on the company’s 8.75% Cumulative Redeemable Preferred Stock.

    On December 3, 2021, IMPP reported about its spin-off completion from StealthGas Inc. The Company’s shares of common stock started trading on the Nasdaq Capital Market on December 6, 2021.

    Conclusion

    IMPP stock performance lessened by 85% from the past few months as the economic conditions are on the declining verge due to pandemics. The current dip in the stock is likely the outcome of the recent statement of pricing of the upsized public offerings.

  • Here’s why iStar Inc. (STAR) Stock Losing its Momentum in Premarket

    Here’s why iStar Inc. (STAR) Stock Losing its Momentum in Premarket

    iStar Inc. (STAR) is engaged in providing advanced level and effective ground lease on established assets. The company utilizes its local investment system, finance fortes, and gross lease to increase the usage of the ground lease. The company had closed up to $40 billion transactions in two decades.

    The price of STAR stock during the regular trading on January 28, 2021, was $21.22 with a gain of 2.51%. At last check in the premarket on January 31, 2022, the stock dipped by 15.1%.

    STAR: Events and Happenings

    On January 28, 2022, STAR reported about its common and preferred stock 2021 dividends’ tax treatment. On December 1, 2021, STAR reported about the modification to its conversion rate of 3.125% Convertible Senior Notes payable by 2022 as an outcome of common stock cash dividends rewarded on December 15, 2021.

    STAR: Key Financials

    On November 2, 2021, STAR announced its financial results for the third quarter ended September 30, 2021. Some of the key points are as follows.

    Net Income per Share

    Basic and diluted net income per share in Q3 2021 was $130.9 million or $1.71 (basic) and 1.51 (diluted) compared to $6.5 million or $0.03 (loss) in the same period of 2020.

    Revenue

    Revenue in the third quarter of 2021 was $195.4 million compared to $115 million in the same period of 2020.

    Assets

    Total current assets recorded for the company in Q3 2021 were $1358 million.

    On October 29, 2021, STAR reported about the receipt of the requisite nod to implement the modifications to the indentures of its 4.75% Senior Notes due 2024, 2025, and 2026 in relation to solicitation of approval from the holders.

    On September 22, 2021, STAR reported about the public pricing of its underwritten offering of 2,200,000 shares of its common stock. The shares were offered at a price of $76.00 per share to the public and net proceeds obtained were $167.2 million.

    Conclusion

    STAR stock downfall from the past six months period by 13% due to declining economic conditions. The current premarket drop in the stock is the consequence of the tax treatment announcement for 2021 dividends. The analysts have advised the company to plan the measures to attract potential investors.

  • Calliditas Therapeutics AB (publ) (CALT) Stock Inclining in Premarket, Here’s why.

    Calliditas Therapeutics AB (publ) (CALT) Stock Inclining in Premarket, Here’s why.

    Calliditas Therapeutics AB (publ) (CALT) is a biotherapeutics company engaged in the development and marketing of innovative treatments for hepatic and kidney disorders. The company’s lead product is TARPEYO which is the sole therapeutics used in the reduction of proteinuria.

    The price of CALT stock during the regular trading on January 28, 2021, was $19.75 with a significant increase of 5.33%. At last check in the premarket on January 31, 2022, the stock gained further momentum by 2.38%.

    CALT: Events and Happenings

    CALT reported about the preliminary sales and commercial accessibility of one of its lead products TARPEYO on January 28, 2022. It is used for treating IgA nephropathy. TARPEYO is the pioneer and only FDA-accepted therapeutics in this disorder.

    CALT: Key Financials

    On November 18, 2021, CALT reported its interim financial results for the three months ended September 30, 2021. Some of the key updates are as follows.

    Profit/Loss per Share

    Basic and diluted profit per share for the quarter in 2021 was SEK 6.4 million or SEK 0.21 compared to a loss of SEK 138 million or SEK 2.77 in the same period of 2020.

    Net Sales

    Net sales for the quarter in 2021 were SEK 198.2 million compared to no net sales for the same period of 2020.

    Assets

    Total current assets recorded for the company were SEK 1256 million.

    On November 3, 2021, CALT reported that the management presented at the Virtual American Society of Nephrology Annual Kidney Week 2021 conference held on November 2-7, 2021. On October 7, 2021, CALT reported controlling Genkyotex SA’s 100% share capital.

    CALT reported on September 16, 2021, about the continuation of the marketing authorization application assessment of Nefecon by the European Medicine Agency’s Committee for Human Medicinal Products.

    Conclusion

    CALT stock decelerated 32% from the past six months due to economic downsizing as a result of pandemics. The stockholders are showing their interest because of the latest announcement by the company regarding the commercial availability of TARPEYO. The analysts are predicting it to be a great breakthrough for the company in terms of revenue generation.

  • Better Choice Company Inc. (BTTR) Stock Gaining Momentum in aftermarket Despite Visible Reason

    Better Choice Company Inc. (BTTR) Stock Gaining Momentum in aftermarket Despite Visible Reason

    Better Choice Company Inc. (BTTR) is a leading pet wellness company making innovative products for dogs and cats. The company develops and markets dog and cat food including food from whole meat and raw-diet dog food.

    The price of BTTR stock during the regular trading on January 28, 2021, was $2.12 with a significant decrease of 9.40%. At last check in the aftermarket, the stock gained momentum by 8.96%.

    BTTR: Events and Happenings

    BTTR reported on January 24, 2022, that it rang the NYSE opening bell on the same date. On January 05, 2022, BTTR reported that the company’s Executives presented at the Virtual ICR Conference 2022 held on January 10-12, 2022.

    On December 22, 2021, BTTR reported about the reacquisition of supplementary $326,000 of its common stock at a price of $3.43 per share. In 2021, the company reacquired up to $1.6 million of outstanding shares of its common stock. On December 15, 2021, BTTR reported that its customers grabbed $2.6 million Halo products at the online shopping event Singles Day.

    On December 02, 2021, BTTR reported that the company’s Executives presented at the 10th Annual ROTH Deer Valley Corporate Access Event held on December 8-11, 2021.

    BTTR: Key Financials

    On November 10, 2021, BTTR reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Income/Loss per Share

    Net income in Q3 2021 was $8.4 million compared to a net loss of $29.5 million in the same period of 2020. Basic and diluted income per share in Q3 2021 was $0.48 and $0.34 respectively against a loss of $3.65 per share.

    Assets

    Total current assets recorded for the company in Q3 2021 were $47.9 million.

    On October 7, 2021, BTTR reported about its entry into a contract with 154 Agency to run its online marketing campaign.

    Conclusion

    BTTR stock downplayed 44% from the past six months period due to the worst pandemic crisis. The investors and shareholders are showing their interest in the company’s policies which resulted in the stock price surge. The current aftermarket stock showed positive signs due to uncertain reasons as there is no recent news to point for the activity.

  • Xeris Biopharma Holdings, Inc. (XERS) Stock Tumbling in Aftermarket, Here’s What you Should Know.

    Xeris Biopharma Holdings, Inc. (XERS) Stock Tumbling in Aftermarket, Here’s What you Should Know.

    Xeris Biopharma Holdings, Inc. (XERS) is an innovative biotherapeutics company. The company is engaged in the development and marketing of treatments for patients with gastroenterological, neurological, and endocrinological issues. The lead product of the company includes Gvoke and Keveyis used for treating severe hypoglycemia and primary periodic paralysis respectively.

    The price of XERS stock during the regular trading on January 28, 2021, was $2.07 with an increase of 3.50%. At last check in the aftermarket, the stock fell by 9.18%.

    XERS: Events and Happenings

    On January 28, 2022, XERS reported about the submission of form 8-K or a report of unscheduled corporate events or material events. On January 18, 2022, XERS reported about the business update and reiterated its 2021 net sales. The initial full-year 2021 net sales were expected to be approximately $76-80 million (55% increase than 2020).

    On Jan. 13, 2022, XERS subsidiary selected PANTHERx Rare as the proprietary pharmacy distributor for Recorlev. It is FDA approved for treating endogenous hypercortisolemia in Cushing’s syndrome patients. On January 6, 2022, XERS reported that the company’s Executives presented at the Virtual H.C. Wainwright BioConnect 2022 conference held on January 10-13, 2022.

    On January 3, 2022, XERS reported about its entry into a contract of securities acquisition of a private placement for net proceeds of up to $30 million. The company issued 10,238,908 shares of its common stock at an acquisition price of $2.93 per share. Also, it issued the warrants for the acquisition of 5,119,454 shares at an exercise price of $3.223 per share.

    On December 30, 2021, XERS reported about the approval of the safety and effectiveness of Recorlev by the FDA. On December 16, 2021, XERS reported about the launch of Ogluo by its marketing collaborator ‘Tetris Pharma’ in the UK.

    XERS: Key Financials

    On November 10, 2021, XERS reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic ad diluted net loss per share in Q3 2021 was $26.0 million or $0.39 compared to $16 million or $0.35 in the same period of 2020.

    Assets

    Total current assets recorded for the company in Q3 2021 were $124.3 million.

    Conclusion

    XERS stock dipped 32% in the last six months due to negative economic growth conditions as a result of COVID-19. The analysts are of the view that the company’s policies to attract investors are sound and will enhance its reputation in the future. The current aftermarket decline in stock price is likely being associated with the 8-K form submission.

  • AgriFORCE Growing Systems, Ltd. (AGRI) Stock is Up in Aftermarket, Here’s why.

    AgriFORCE Growing Systems, Ltd. (AGRI) Stock is Up in Aftermarket, Here’s why.

    AgriFORCE Growing Systems, Ltd. (AGRI) is a leading company aimed at developing automated growth platforms for agriculture products. AGRI utilizes hydroponics techniques for the growth of different agri-based products. The company is also engaged in refining the methods used in controlled-environment agriculture.

    The price of AGRI stock during the regular trading on January 28, 2022, was $1.21 with an incline of 2.66%. At last check in the aftermarket, the stock further surged significantly by 8.14%.

    AGRI: Events and Happenings

    On January 28, 2022, AGRI reported that the company’s Executives will present at the Virtual Winter Wonderland Best Ideas Investor Conference being held on February 8-11 2022. On January 11, 2022, AGRI updated about its purchase plan of a principal European consultancy of agri-tech for its optimization and operational skills.

    AGRI reported about its entry into a definitive partnership with Humboldt Bliss, Ltd. on December 02, 2021. The main purpose of the collaboration is the placement of the company’s foundational IP. The main facilities provided by Humboldt include a growing platform for the growth and marketing of important agri-based products.

    On November 24, 2021, the company reported that its Executives presented at the following investor conferences held virtually.

    • Canaccord Genuity 2ndAnnual AgriFood Tech Innovations Forum held on December 2, and
    • Benzinga All Access Event also held on December 2, 2021.

    AGRI: Key Financials

    On November 15, 2021, AGRI reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.

    Assets

    Total current assets during the period were reported to be $10.3 million.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $1.82 million or $0.14 against $0.97 million or $0.12 in the same period of 2020.

    On November 10, 2021, the company reported that its Executives presented at the Virtual 10th Annual Roth Technology & Inaugural AgTech Answers Event held on November 16-18, 2021.

    Conclusion

    AGRI stock underplayed during the last six months period as its price declined by 66% over the period. This downfall is the result of global pandemic recessive economic growth. The company announced its participation at an Investor Conference, resultantly the stock price in aftermarket increased. The analysts had shown confidence in the company’s policies.

  • Hall of Fame Resort & Entertainment Company (HOFV) Stock Volatile in the Early Trading. Here’s the Reason.

    Hall of Fame Resort & Entertainment Company (HOFV) Stock Volatile in the Early Trading. Here’s the Reason.

    Hall of Fame Resort & Entertainment Company (HOFV) is a leading entertainment related company engaged in pro football business. The company leverages the popularity of football professionals in collaboration with pro football. The company possesses leading media, sports and entertainment businesses across the globe.

    The price of the company’s stock during the regular trading on January 27, 2022 was $1.14 with a surge of 1.7%, giving back gains made earlier today.

    HOFV: Events and Happenings

    On January 27, 2022, HOFV reported about its entry into a ten-year collaboration with Genesis Global Ltd. After the agreement, Genesis will be the authorized mobile sports-betting collaborator of the Company. On January 12, 2022, HOFV reported about achievements of season two NFL Alumni Academy. HOFV reported on January 10, 2022 about its entry into a contract regarding content development with Rashad Jennings. He is the leading businessperson and ex NFL running back.

    On January 5, 2021, HOFV reported that the Atlanta Hot Wings became the pioneer winner in the Hall of Fantasy League, after beating Boston Barflies. HOFV reported about its entry into a 10-year partnership with Rush Street Interactive, Inc. on December 23, 2021. Both the companies agreed upon the allowance for leading sports betting location’s process.

    On December 20, 2021, the company reported about its entry into a partnership with SMOOSH Cookies for bringing its pioneer location to the HOFV. HOFV reported about its entry into a multi-million-dollar partnership with ForeverLawn, Inc. on December 7, 2021. Both parties agreed upon making ForeverLawn the authorized synthetic turf collaborator of HOFV.

    On December 1, 2021, HOFV reported that the company’s Executives presented at Truist Securities Gaming, Lodging, Leisure and Restaurants Summit 2021 held on December 9, 2021.

    HOFV: Key Financials

    On November 10, 2021, HOFV reported its financial results for third quarter ended September 30, 2021. Some of the key points are as follows.

    Revenue

    Revenue in Q3 2021 was $3.5 million compared to $1.67 million in the same period prior year. The company recorded revenue increase of 108% over the year.

    Net Income

    Net income in Q3 2021 was recorded $8.1 million against net loss of $8.3 million in the same period of 2020.

    Conclusion

    HOFV stock is on a declining verge from the past six months period due to recessive economic conditions in pandemic. The recent gain in the early trading hours, as suggested by the experts, is the outcome of its long-term agreement with a leading company. The analysts are hoping that the company will reap the benefits of current collaborations in the future in the form of heavy investment.

  • Mesa Royalty Trust (MTR) Stock Trading Higher Today. Here’s the Reason.

    Mesa Royalty Trust (MTR) Stock Trading Higher Today. Here’s the Reason.

    Mesa Royalty Trust (MTR) is a leading company focused on the development and commercialization of mineral products globally.  The company supplies various products including bentonite, chromite and leonartide related products. The consumer base of the company includes paper, steel, construction, energy and polymer industries.

    The price of MTR stock during the regular trading on January 26, 2022 was $8.8 with a significant gain of 4.44%. At last check in the current market on January 27, 2022, the stock was further up by 2%.

    MTR: Events and Happenings

    On January 26, 2022, MTR reported about the declaration of its common stock’s $0.05 per share quarterly dividend to shareholders, payable by March 10, 2022. On January 17, 2022, MTR reported about its fourth quarter earnings release date to be February 3, 2022.

    MTR reported about its entry into two long-term strategic collaborations on December 16, 2021. The company agreed upon with Asia Symbol for the deployment of ground calcium carbonate system. The contract represented the company’s preliminary GCC satellite offering for its packaging consumers. The company also signed contract with Seshasayee Paper and Boards Ltd. for the construction of its 22,000 metric tonnes per year precipitated calcium carbonate portfolio.

    MTR: Key Financials

    On November 4, 2021, MTR reported its financial results for the third fiscal quarter ended October 3, 2021. Some of the key updates are as follows.

    Net Sales

    Total net sales in Q3 2021 were $473.2 million compared to $388.3 million in the same period of 2020. Overall, the company recorded 22% sales growth over the year.

    Net Income per Share

    Basic and diluted net income per share in Q3 2021 was $41.4 million or $1.24 (basic) and $1.22 (diluted) compared to $28.3 million or $0.83 in the same period in 2020.

    Assets

    Total current assets in Q3 2021 were recorded to be $1029.8 million.

    MTR reported on October 25, 2021, about the approval of its $75 million share reacquisition program by the BoDs. The program operated with immediate effect.

    Conclusion

    MTR stock is outdoing from the past six months as the stock improved by 52% during that period despite the economic challenges in the pandemic. The current premarket incline in stock is probably the product of declaration of quarterly dividend by the company. The financial experts are praising the company for its brilliant performance and potential investor attraction.

  • Xilinx, Inc. (XLNX) Stock Gaining Momentum in Premarket. Here’s why.

    Xilinx, Inc. (XLNX) is a leading developer of computational portfolios enabling the novelty across the cloud, edge and the endpoint. The programs developed by the company are flexible and adaptive in nature. The lead products of the company include FPGA, ACAP and Adaptive SoCs.

    The price of XLNX stock during the regular trading on January 26, 2022 was $175.3 with a slight increase of 1.28%. At last check in the premarket on January 27, 2022, the stock further inclined by 3.77%.

    XLNX: Key Financials

    On January 26, 2022, XLNX reported its financial results for the third fiscal quarter ended January 1, 2022. Some of the key updates are as follows.

    Revenue

    Total net revenue in Q3 2022 was $1011 million compared to $803 million in the same period of 2021. Overall, the company recorded 26% growth in the revenue over the year period.

    Net Income per Share

    Basic and diluted net income per share in Q3 2022 was $300 million or $1.19 compared to $171 million or $0.69 in the same period in 2021.

    XLNX: CEO Comments

    Speaking at the occasion, XLNX CEO Victor Peng stated that the company accomplished another milestone of $1 billion sales in the quarter for the first time. He further added that the company’s supply conditions were limited but it catered its customer’s needs very well.

    XLNX: Events and Happenings

    On November 15, 2021, XLNX reported that the company’s Executives presented at the SC21 supercomputing conference. The management reported about its innovative data center accelerator card known as Alveo U55C. The company also introduced a novel clustering solution for the large-scale deployment of FPGAs.

    On October 25, 2021, XLNX updated about providing production-ready streaming endpoint solution via its system integrator portfolio. The systems used for the process include Zynq-7000 SoC tools and Zynq® UltraScale+™ EV Multi-Processor SoC.

    Conclusion

    XLNX is outperforming from the last six months despite the challenges faced due to the pandemic. The company’s stock surged by 33% from the past six months and is on inclining verge in the recent premarket. The current rise in stock price is likely the outcome of positive financial results for third fiscal 2021. The analysts are pinpointing the company to be one of the next generation leaders.